Wingen Marleen, Kuypers Kim P C, Ramaekers Johannes G
Faculty of Psychology, Department of Neurocognition (Experimental Psychopharmacology Unit), Brain and Behaviour Institute, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
Psychopharmacology (Berl). 2007 Feb;190(3):391-400. doi: 10.1007/s00213-006-0614-x. Epub 2006 Nov 24.
Various studies have demonstrated a modulating role for serotonin in attention. Selective serotonin inhibitors have repeatedly been shown to impair performance in sustained attention tasks.
To assess the contribution of serotonin reuptake inhibition and specific blockade of the pre-synaptic 5-HT(1a) receptor and the 5-HT(2a) receptor to deficits in attention.
The study was conducted according to a randomized, double-blind, placebo controlled, four-way crossover design including 16 healthy volunteers. Treatments consisted of oral administration of the selective serotonin reuptake inhibitor (SSRI) escitalopram 20 mg + placebo; escitalopram 20 mg + ketanserin (5-HT(2a) antagonist), 50 mg; escitalopram 20 mg + pindolol (5-HT(1a) antagonist) 10 mg; and placebo + placebo on four separate days. A range of performance tasks were conducted to assess the subjects' attention and motor functions.
Escitalopram administered alone impaired tracking performance in a divided attention task. The combination of escitalopram and pindolol and escitalopram and ketanserin impaired divided attention as compared to placebo. In addition, escitalopram and ketanserin impaired sustained attention. Divided attention impairment observed after combined treatments did not significantly differ from impairments after escitalopram alone. Sustained attention impairment observed after combined escitalopram and ketanserin significantly differed from escitalopram alone.
5HT(1a) blockade hardly affected SSRI effects on attention. Additional 5HT(2a) blockade, however, produced impairments of sustained attention and motor impulse control.
多项研究已证明血清素在注意力方面具有调节作用。选择性血清素抑制剂反复被证明会损害持续注意力任务中的表现。
评估血清素再摄取抑制以及突触前5-羟色胺(5-HT)1a受体和5-HT2a受体的特异性阻断对注意力缺陷的影响。
该研究按照随机、双盲、安慰剂对照、四向交叉设计进行,纳入16名健康志愿者。治疗方案包括口服选择性血清素再摄取抑制剂(SSRI)艾司西酞普兰20毫克 + 安慰剂;艾司西酞普兰20毫克 + 酮色林(5-HT2a拮抗剂)50毫克;艾司西酞普兰20毫克 + 吲哚洛尔(5-HT1a拮抗剂)10毫克;以及安慰剂 + 安慰剂,分四天进行。进行了一系列表现任务以评估受试者的注意力和运动功能。
单独使用艾司西酞普兰会损害分散注意力任务中的追踪表现。与安慰剂相比,艾司西酞普兰与吲哚洛尔以及艾司西酞普兰与酮色林的组合会损害分散注意力。此外,艾司西酞普兰和酮色林会损害持续注意力。联合治疗后观察到的分散注意力损害与单独使用艾司西酞普兰后的损害无显著差异。艾司西酞普兰和酮色林联合使用后观察到的持续注意力损害与单独使用艾司西酞普兰有显著差异。
5-HT1a受体阻断对SSRI对注意力的影响几乎没有作用。然而,额外的5-HT2a受体阻断会导致持续注意力和运动冲动控制受损。